Readystate Asset Management’s Janux Therapeutics JANX Stock Holding History

Readystate Asset Management’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.52M	Sell	109,425 -776,470	-88%	-$10.6M	0.07%	184
2025 Q4	$12.2M	Sell	885,895 -74,484	-8%	-$1.75M	0.5%	51
2025 Q3	$23.5M	Buy	960,379 +264,423	+38%	+$6.44M	1%	23
2025 Q2	$16.1M	Buy	695,956 +419,396	+152%	+$11.1M	0.49%	47
2025 Q1	$7.47M	Sell	276,560 -63,079	-19%	-$2.38M	0.25%	73
2024 Q4	$18.2M	Buy	339,639 +307,304	+950%	+$16.3M	0.56%	36
2024 Q3	$1.47M	Buy	+32,335	New	+$1.41M	0.03%	383

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Readystate Asset Management's JANX Position: Q1 2026 in Review

Readystate Asset Management reduced its Janux Therapeutics (JANX) stake by 88% in Q1 2026, selling an estimated $10.6M and leaving 109,425 shares worth $1.52M. The position accounts for 0.07% of the portfolio, ranked #184.

Readystate Asset Management first reported a position in JANX in Q3 2024 and has held it in 7 quarters since. The position peaked at $23.5M in Q3 2025. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

Readystate Asset Management held 109,425 shares of Janux Therapeutics worth $1.52M as of Q1 2026.
Readystate Asset Management sold 776,470 Janux Therapeutics shares in Q1 2026, an estimated $10.6M.
Janux Therapeutics made up 0.07% of Readystate Asset Management's portfolio in Q1 2026, its #184 holding.
Readystate Asset Management first reported a position in Janux Therapeutics in Q3 2024 and has held it in 7 quarters since.
Readystate Asset Management's Janux Therapeutics position peaked at $23.5M in Q3 2025.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Readystate Asset Management's 13F filing for Q1 2026, filed 15 May 2026.